{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:18:13Z","timestamp":1787015893397,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Photoderm Photoimm Photomed"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Broad\u00a0spectrum sunscreens with a sun protection factor (SPF) of 15 or greater are indicated to decrease the risk of skin cancer and early skin aging caused by the sun if used as directed with other sun protection measures. To determine whether sunscreen product performance is compromised under solar exposure and to test spectral uniformity of protection across the UVA spectrum, we tested broad\u00a0spectrum sunscreens with a variety of active pharmaceutical ingredients (APIs) and in a variety of dosage forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross\u2010sectional market survey of 32 sunscreen drug products containing either organic or inorganic APIs with SPFs of 15, 30, 50, and 70 was tested. UV doses were delivered via natural sun in Silver Spring, Maryland between June and September of 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 32 sunscreen drug products, 6 products failed to meet their broad\u00a0spectrum claim under solar exposure. Using FDA's new proposal to strengthen sunscreen broad spectrum requirements, spectral uniformity based on the mean sunscreen absorbance of UVA1(340\u2010400\u00a0nm)\/UV (290\u2010400\u00a0nm) indicated that ~40% of sunscreen drug products tested had suboptimal UVA protection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>US consumers may unknowingly be receiving up to 36% more transmitted UVA when selecting between similarly labeled broad spectrum sunscreen drug products with equivalent SPF values. FDA's new proposal may help decrease consumers' overall lifetime UVA burden. Spectral absorbance data on sunscreen performance can be used to further improve the coupling of broad\u00a0spectrum protection to a product's SPF value so that consumers have improved proportional increases in UV protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/phpp.12503","type":"journal-article","created":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T06:58:48Z","timestamp":1564815528000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Suboptimal UVA attenuation by broad spectrum sunscreens under outdoor solar conditions contributes to lifetime UVA burden"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-6776","authenticated-orcid":false,"given":"Sergio G.","family":"Coelho","sequence":"first","affiliation":[{"name":"Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Office of New Drugs Center for Drug Evaluation and Research, Food and Drug Administration Silver Spring Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rua","sequence":"additional","affiliation":[{"name":"Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Office of New Drugs Center for Drug Evaluation and Research, Food and Drug Administration Silver Spring Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Radiological Health, Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health, Food and Drug Administration Silver Spring Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Division of Biomedical Physics, Office of Science and Engineering Laboratories Center for Devices and Radiological Health, Food and Drug Administration Silver Spring Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0865fje"},{"key":"e_1_2_8_3_1","unstructured":"U.S. Department of Health and Human Services.The Surgeon General's Call to Action to Prevent Skin Cancer. Washington DC: U.S. Dept of Health and Human Services Office of the Surgeon General;2014."},{"key":"e_1_2_8_4_1","unstructured":"U.S. Food and Drug Administration.Sunscreen Drug Products for Over\u2010The\u2010Counter Human Use; Proposed Rule. In: Department of Health and Human Services ed. Vol84: Federal Register;2019:6204\u20136275."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5586"},{"key":"e_1_2_8_6_1","unstructured":"29th Hawaii State Legislature.Environment; Water Pollution; Sunscreen; Oxybenzone; Octinoxate; Sale; Distribution; Prohibition.SB2571 SD2 HD2 CD12018; 1\u20106.https:\/\/www.capitol.hawaii.gov\/Archives\/measure_indiv_Archives.aspx?billtype=SB&billnumber=2571&year=2018. Accessed June 6 2019."},{"key":"e_1_2_8_7_1","unstructured":"City of Key West Florida.Requesting the Key West Sustainability Board to report to the City Commission on the efficacy of sunscreens that do not contain Oxybenzone and Octinoxate and on other factors affecting the Coral Reef surrounding Key West. 19\u20103516 2019;https:\/\/keywest.legistar.com\/LegislationDetail.aspx?ID=3847999&GUID=61C56230-C9F6-40AA-9AE4-9998D80064AF&Options=ID|Text|&Search=oxybenzone. Accessed June 6 2019."},{"key":"e_1_2_8_8_1","unstructured":"U.S. Food and Drug Administration.FDA advances new proposed regulation to make sure that sunscreens are safe and effective. 2019;https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-advances-new-proposed-regulation-make-sure-sunscreens-are-safe-and-effective. Accessed June 6 2010."},{"key":"e_1_2_8_9_1","unstructured":"National Toxicology Program.Report on Carcinogens Background Document for Ultraviolet (UV) Radiation Broad Spectrum and UVA UVB and UVC. 2000:120."},{"key":"e_1_2_8_10_1","unstructured":"International Agency for Research on Cancer.Solar and ultraviolet radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol100D: IARC Monogr Eval Carcinog Rish Chem Hum;2012:68."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.5.501"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.762"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112400"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2008.04.006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp166"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.016"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316632072"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.024"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2359"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1893"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1256022"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1039\/C2PP25323B"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.283"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10161.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1998.tb03253.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2009.00656.x"},{"key":"e_1_2_8_27_1","unstructured":"U.S. Food and Drug Administration.Sunscreen Drug Products for Over\u2010the\u2010Counter Human Use; Proposed Amendment of Final Monograph. In: Department of Health and Human Services ed. Vol72: Federal Register;2007:49070\u201049122."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2494.2008.00471.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.07.043"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2005.00143.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3453"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0028"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01425.x"},{"key":"e_1_2_8_34_1","first-page":"285","volume-title":"Sunscreens Development, Evaluation and Regulatory Aspects","author":"Klein K","year":"1997"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.10.1319"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1039\/C2PP25127B"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22745"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.6069"},{"key":"e_1_2_8_39_1","first-page":"39","article-title":"COMMISSION RECOMMENDATION of 22 September 2006 on the efficacy of sunscreen products and the claims made relating thereto (2006\/647\/EC)","volume":"265","author":"European Commission","year":"2006","journal-title":"Official Journal"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.01.040"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-7-1"}],"container-title":["Photodermatology, Photoimmunology &amp; Photomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/phpp.12503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/phpp.12503","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/phpp.12503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T06:25:57Z","timestamp":1694154357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/phpp.12503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/phpp.12503"],"URL":"https:\/\/doi.org\/10.1111\/phpp.12503","archive":["Portico"],"relation":{},"ISSN":["0905-4383","1600-0781"],"issn-type":[{"value":"0905-4383","type":"print"},{"value":"1600-0781","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"2019-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}